듀켐바이오

176750KOSDAQ의약품 제조업

47.0 / 100

Reference Date: 2026-04-13

Financial Score15.0 / 40

News Sentiment15.0 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Declined 7.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Dukem Bio is a company specializing in the development, manufacturing, and sales of radiopharmaceuticals for cancer and brain diseases, holding the largest number of PET-CT radiopharmaceutical products in South Korea. In 2025, it achieved revenue of 38.57 billion won and operating profit of 7.44 billion won, maintaining a market share leadership in key product lines such as FDG and Alzheimer's diagnostic agents. By acquiring RadioDnS Labs in 2024, the company is enhancing its R&D capabilities and aiming to become a global leader in radiopharmaceuticals.

Number of Employees

144people

Average Salary

44.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

39.13Industry Average 14.800.0Point

2.6x industry avg (risky)

PBR

5.18Industry Average 1.040.0Point

5.0x industry avg (risky)

ROE

14.05Industry Average 4.427.0Point

3.2x industry avg (excellent)

Debt Ratio

20.42Industry Average 11.980.5Point

1.7x industry avg (risky)

Trend 2024~20257.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.3% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲46.6% (1-year basis)

ROE Trend

2.5 / 4

Avg ROE 19.4% (declining, 2yr)

Detailed News Sentiment

4 totalPositive 0Neutral 2Negative 0Average Sentiment Score 70

Neutral
매출 0원인데 공모가 1.6만원?...‘나노 MRI 조영제’ 인벤테라 ...
나노의약품 개발 기업 인벤테라가 코스닥 기술 특례 상장에 도전하며 철 기반 나노 MRI 조영제를 앞세워 진단 신약 시장에 진출한다는 내용으로, 듀켐바이오와 직접적인 관련은 없습니다.
Neutral
인벤테라 "내년 INV-002 제품 출시, 기술이전으로 성장 잠재력"
인벤테라가 내년 INV-002 제품 출시와 기술이전에 힘입어 높은 수익성을 예상하며 2029년 영업이익 222억원을 목표로 한다는 내용으로, 듀켐바이오와 직접적인 관련은 없습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (14%, downtrend)

Current 8,960Won52-week high 12,00052-week low 8,430

1-month return1.0Point

1m -7.53% (falling)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral정기주주총회결과2026-03-26
Neutral주식매수선택권부여에관한신고2026-03-26
Neutral[기재정정]주식매수선택권부여에관한신고2026-03-26
Neutral사업보고서 (2025.12)2026-03-18
Neutral감사보고서제출2026-03-18